NASDAQ:CMRX - Chimerix Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$4.73 -0.01 (-0.21 %)
(As of 07/16/2018 04:00 PM ET)
Previous Close$4.74
Today's Range$4.68 - $4.75
52-Week Range$4.17 - $5.94
Volume78,400 shs
Average Volume193,475 shs
Market Capitalization$226.35 million
P/E Ratio-3.11
Dividend YieldN/A
Beta1.32
Chimerix logoChimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside that is in Phase I clinical trials for the treatment and prevention of norovirus; and CMX157, a nucleoside analog, which is in Phase II clinical trials to treat HIV and hepatitis B virus infection. The company has license agreements with ContraVir Pharmaceuticals for the development and commercialization of CMX157 for various antiviral indications; and Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

Receive CMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CMRX
CUSIPN/A
Phone919-806-1074

Debt

Debt-to-Equity RatioN/A
Current Ratio18.21
Quick Ratio18.21

Price-To-Earnings

Trailing P/E Ratio-3.11
Forward P/E Ratio-2.67
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.49 million
Price / Sales50.30
Cash FlowN/A
Price / CashN/A
Book Value$4.71 per share
Price / Book1.00

Profitability

EPS (Most Recent Fiscal Year)($1.51)
Net Income$-70,980,000.00
Net Margins-1,736.95%
Return on Equity-31.97%
Return on Assets-30.64%

Miscellaneous

Employees82
Outstanding Shares47,750,000
Market Cap$226.35

The Truth About Cryptocurrencies

Chimerix (NASDAQ:CMRX) Frequently Asked Questions

What is Chimerix's stock symbol?

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

How were Chimerix's earnings last quarter?

Chimerix Inc (NASDAQ:CMRX) released its earnings results on Monday, May, 7th. The biopharmaceutical company reported ($0.42) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.43) by $0.01. The biopharmaceutical company earned $0.79 million during the quarter, compared to analyst estimates of $1.12 million. Chimerix had a negative return on equity of 31.97% and a negative net margin of 1,736.95%. View Chimerix's Earnings History.

When is Chimerix's next earnings date?

Chimerix is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Chimerix.

What price target have analysts set for CMRX?

3 Wall Street analysts have issued twelve-month price targets for Chimerix's stock. Their forecasts range from $6.00 to $10.00. On average, they anticipate Chimerix's share price to reach $8.00 in the next year. This suggests a possible upside of 69.1% from the stock's current price. View Analyst Ratings for Chimerix.

What is the consensus analysts' recommendation for Chimerix?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."

What are Wall Street analysts saying about Chimerix stock?

Here are some recent quotes from research analysts about Chimerix stock:
  • 1. HC Wainwright analysts commented, "We think this announcement bodes well for the development and potential approval for brincidofovir for smallpox. As a reminder, oral brincidofovir is being developed for smallpox under the FDA’s Animal Rule, which allows for testing of investigational drugs in animal models to support effectiveness in diseases that are not ethical or feasible to study in humans. Results from a study of brincidofovir in a rabbit model of smallpox showed improved survival, even when treatment was initiated during the course of disease. In the pivotal Phase 3 study for the treatment of smallpox conducted in the rabbitpox model, brincidofovir achieved statistically significant (p<0.05) reductions in mortality in brincidofovir treated animals in comparison to placebo group."" (6/7/2018)
  • 2. According to Zacks Investment Research, "Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. " (5/7/2018)

Who are some of Chimerix's key competitors?

Who are Chimerix's key executives?

Chimerix's management team includes the folowing people:
  • Dr. M. Michelle Berrey, Pres, CEO & Director (Age 51)
  • Mr. Timothy W. Trost, Sr. VP, CFO, Principal Accounting Officer & Corp. Sec. (Age 60)
  • Ms. Linda M. Richardson, Chief Strategy & Commercial Officer (Age 54)
  • Dr. William Garrett Nichols M.D., MS, Chief Medical Officer (Age 49)
  • Dr. Roy W. Ware Ph.D., MBA, Chief Manufacturing & Technology Officer

Has Chimerix been receiving favorable news coverage?

News headlines about CMRX stock have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Chimerix earned a news impact score of 0.14 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 45.17 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of Chimerix?

Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Chimerix's stock price today?

One share of CMRX stock can currently be purchased for approximately $4.73.

How big of a company is Chimerix?

Chimerix has a market capitalization of $226.35 million and generates $4.49 million in revenue each year. The biopharmaceutical company earns $-70,980,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis. Chimerix employs 82 workers across the globe.

How can I contact Chimerix?

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]


MarketBeat Community Rating for Chimerix (NASDAQ CMRX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  247 (Vote Outperform)
Underperform Votes:  243 (Vote Underperform)
Total Votes:  490
MarketBeat's community ratings are surveys of what our community members think about Chimerix and other stocks. Vote "Outperform" if you believe CMRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CMRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.